Talence

France

21 total trials 11 recruiting

Filter these 21 trials by phase, condition, sponsor and more.

Open in Search →

Evaluation of Glucocorticoids Plus Rituximab Compared to Glucocorticoids Plus Placebo for the Treatment of Patients With Newly-Diagnosed or … Pending

2024-516052-17-01 10 Patients with a diagnosis of IgAV according to Chapel Hill Consensus C
Efficacy and safety of circumcision alone on risk of febrile urinary tract infections in boys with posterior urethral valves: a prospective … Pending

2024-519166-48-01 4 Posterior Urethral Valves
Role of Neuroinflammation and Blood-Brain Barrier Breakdown in Intracerebral Hemorrhage. Pending

2025-521923-58-00 4 Intracerebral hemorrhage.
A Study to Evaluate the Treatment Outcomes of Subcutaneous Anifrolumab in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythema … Pending

2025-523670-17-00 5 Systemic lupus erythematosus
Multicentre study evaluating the efficacy of a 7-day course of doxycycline for the treatment of asymptomatic anal lymphogranuloma venereum S … Pending

2025-524978-42-00 4 Asymptomatic anal LGV infection
Cerebral hemodynamic optimization by milrinone for the prevention of delayed cerebral ischemia in severe subarachnoid hemorrhage Recruiting

2024-513410-35-00 5 2026-05-12 aneurysmal subarachnoid hemorrhage
PRODIGE 88-CIRCULATE PAC: Phase III multicentric, open-label, randomized study to investigate the efficacy of chemotherapy in patients with … Recruiting

2023-505046-26-00 5 2026-05-07 Colon carcinoma
FAPI-PET value for the initial screening of pancreatic and biliary cancers (FAPDIG Study) Recruiting

2024-517270-23-00 4 2026-03-05 Cholangiocarcinoma
STOP VEN-IPC 2024-001 DE-ESCALATION STUDY EVALUATING VENETOCLAX AND AZACITIDINE DISCONTINUATION IN AML RESPONDING PATIENTS Recruiting

2024-514112-28-00 4 2026-02-04 acute myeloid leukemia
Study to evaluate the efficacy and safety of [177Lu]Lu-DOTA-TATE in patients with Grade 1 and Grade 2 advanced GEP-NET (NETTER-3) Recruiting

2024-518325-15-00 5 2025-09-08 Gastroenteropancreatic neuroendocrine tumor (GEP-NET)
Safety and efficacy of apixaban versus warfarin in peritoneal dialysis patients with non valvular atrial fibrillation: a randomized controll … Recruiting

2023-507544-37-00 5 2025-01-08 patients with end-stage renal disease on chronic peritoneal dialysis a
PRODIGE 70 - CIRCULATE - CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II Recruiting

2024-515297-27-00 5 2024-08-14 colon carcinoma
NAlmefene versus placebo in addition to treatment as usual on craving in Behavioural Addictions (NABAb) Recruiting

2022-500085-96-00 5 2023-03-31 Patients with gambling disorder or sexual addiction or food addiction
Study evaluating the tailored management of locally-advanced rectal carcinoma Recruiting

2024-511609-44-00 10 2022-02-03 Rectum cancer
Predictive Signature of Benralizumab Response. BENRAPRED Study. Recruiting

2024-514843-27-00 6 2021-10-11 Severe asthma
Prospective multicenter randomized double-blind study comparing caspofungin to placebo for the treatment of ICU yeast intra-abdominal infect … Recruiting

2024-516266-11-00 5 2020-01-06 yeast intra-abdominal infection, peritonitis
PRODIGE 49 - OSCAR: Systemic oxaliplatin or in intra-arterial chemotherapy combined with LV5FU2 ± Irinotecan, and targeted therapy, in first … Ended recruitment

2024-518553-41-00 5 2024-11-08 colon cancer and rectal with liver metastasis
An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended recruitment

2022-503040-41-00 4 2024-02-09 PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
The USTAP CD trial USTekinumab in fistulising Perianal Crohn’s Disease: The USTAP CD study Ended recruitment

2023-503380-42-00 6 2020-11-16 patient with moderate to severe Crohn's disease with at least one acti
First-in-human study of ICT01 in patients with advanced-stage, relapsed/refractory cancer Ended recruitment

2024-515560-30-00 7 2020-03-05 Advanced-stage, relapsed/refractory cancer
PRODIGE 34 - ADAGE: Randomised phase III study evaluating adjuvant chemotherapy after resection of stage III colon adenocarcinoma in patient … Ended recruitment

2024-518741-21-00 4 2014-12-23 colon cancer

Showing 1–21 of 21 trials